Insmed (LTS:0JAV) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JAV Insmed Inc LTS:0JAV
66 GF Score
Price $100.27
GF Value $190.19
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0JAV
66GF Score
Insmed Inc LTS:0JAV
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insmed (LTS:0JAV) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $100.27 is trading 47.3% below its estimated GF Value™ of $190.19. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for LTS:0JAV:

  • Short Ratio:
  • GF Value™: $190.19 vs. price of $100.27 (47.3% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the LTS:0JAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
66GF Score

Get the complete analysis for LTS:0JAV

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.27
Price
$190.19
GF Value